Barclays lowered the firm’s price target on Legend Biotech (LEGN) to $80 from $90 and keeps an Overweight rating on the shares as part of a Q4 earnings preview for the biotechnology group.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LEGN:
- Legend Biotech Reshapes Board, Appoints GenScript Chairman Robin Meng as Director
- Legend Biotech: Undervalued CARVYKTI Leader Offering a Compelling Buy Opportunity Despite Transient Setback
- Legend Biotech price target lowered to $50 from $60 at H.C. Wainwright
- Legend Biotech downgraded to Hold from Buy at TD Cowen
- Legend Biotech falls -12.7%